Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN, highlights 72 week data Vera released in January, and discusses the potential path to market in this space.
Also look for unique social pages for BiotechTV U.
Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.
.png){kind=logo}
